The Myeloma Trial Finder lists the clinical trials that are currently recruiting in the UK. If you are thinking about joining a clinical trial you should talk to your healthcare team to find out if this is a suitable option for you.
Further information can be found on our website under Clinical Trials and Novel Drugs or if you would like to speak to someone, please call the Myeloma Infoline on 0800 980 3332
Last update: 27/07/2023
There are currently 35 open trials
SAR445514 for relapsed/refractory myeloma and relapsed/refractory AL amyloidosis
Relapsed, Refractory, AL amyloidosis
This trial is investigating the safety and effectiveness of SAR445514 for the treatment of relapsed and/or refractory myeloma or AL amyloidosis.
The Christie Hospital, Manchester;
University College Hospital, London
Who can enter the study?:
Relapsed and/or refractory myeloma patients who have had at least two previous lines of treatment which included:
AL amyloidosis patients
Relapsed and/or refractory AL amyloidosis patients who have had at least one previous life of treatment which included:
Patients will receive SAR445514 subcutaneously (an injection into the skin).
Different groups of patients will be given different doses of SAR445514 .
Patients will be required to attend outpatient clinics for regular check-ups and tests for at least 15 months.
(for Medical Professionals):
This is a phase 1/2, first-in-human, dose escalation trial of SAR445514, an NKcell Engager (NKCE) Targeting B-cell Maturation Antigen (BCMA) in Monotherapy in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) and in Relapsed/Refractory Light-chain Amyloidosis (RRLCA)
For more information, click here.